3Cleeman JI. Executive summary of the third report of the national cholesterol edeeation program(NCEP) expert panel on determination, evaluation and treatment of high blood cholesterol in adults(ATP-Ⅲ)[J]. JAMA,2001,285:2486-2497.
4Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial[J]. Lancet, 2002,360 : 7-22.
5PROSPER Study Group. Prospective study of pravastatin in the elderly at risk(PROSPER) [J]. Lancet,2002,360:1673-1679.
6The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcome in moderately hypercholesterolemic, hypertension patients randomized to pravastatin vs usual carse :The Antihypertension and Lipid-Lowering Treatment To Prevent Heart Attack Trial(ALLHAT-LLT) [J]. JAMA, 2002,288 : 2981-2997.
7Sever PS,Dahlof B,Poulter NR,et al. Protection of coronary and stroke events with atorvastatin in hypertension patients who have average or lower-than-average cholesterol concentration, in the Angio-Scandinavian Cardiac Outcomes Trial-Lipid LoweringArm(ASCOT-ALL) : a multicentre rand omized controlled trial[J]. Lancet,2003,361 : 1149-1158.
8Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial[J]. JAMA, 2004,291 : 1071-1080.
9Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med,2004,350:1495-1504.
10Grundy SM, Cleeman JI, Merz CN, et al. National Heart , Lung,and Blood Institute;American College of Cardiology Foundation;American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines[J]. Circulation, 2004,110 : 227-239.
二级参考文献4
1[17]Cleeman JI. Executive summary of the third report of the national cholesterol education program(NCEP) ex pert panel on determination, evaluation and treatment of high blood cholesterol in adults(ATP- lll)[J ]. JAMA, 2001,285: 2486 - 2497
2[18]Singh BK,Mehta J. Management of dyslipidenia in thc primary prevention of coronary heart disease[ J ]. Corr Opin in Cardiolo,2002,17:503 - 511
3[19]Bybee KA, Wrigh S, Kopecky S. Effect of early statin therapy after acute coronary syndromes: a concise review of the recent data[J ]. Cardiolo in Revi, 2002,10:301 - 305
5Takahide-Kohm MD,Dobun-Hayashi MD,Yoshihiro-Okada MD,et al.Effects of medication on cardiovascular events in the japanese coronary artery disease(JCAD)study.Circ J,2007,71:1835-1840.
6Hiroaki-Takashima MD,Yukio-Ozaki MD,Tatsuya-Yasukawa MD,et al.Impact of lipid lowering therapy with pitavastain,a new HMG-CoA reductase inhibitor regressior of coronary atherosclerotic plaque-a 3 Dimensional intravascular ultrasound study.Circulation Journal,2007,71:1678-1684.
3Jolien de Jager,Adriaan Kooy,Philippe Lehert,Michiel G Wulffele,Jan van der Kolk,Daniel Bets,Joop Verburg,Ab J M Donker,Coen D A Stehouwer,许翎岭(译).二甲双胍长期治疗2型糖尿病患者以及维生素B12缺乏的危险性：随机安慰剂对照研究（摘要）[J].英国医学杂志中文版,2010,13(5):304-305. 被引量：2
